News & Updates

Treatment with ranolazine in combination with class III antiarrhythmic drugs (AADs) is associated with improved maintenance of sinus rhythm (SR) 1 year after DC cardioversion (DCCV) relative to class III AAD alone, according to a study presented at EHRA 2024.

The use of a venous closure system (VCS) post ablation for atrial fibrillation (AF) shortens ambulation time without recurrence of bleeding in the STYLE-AF study presented at EHRA 2024.

Treatment of monomorphic ventricular tachycardia (VT) with a novel ultra-low-temperature cryoablation catheter (vCLAS) eliminates VT in most patients with ischaemic or non-ischaemic cardiomyopathy in the first-in-human Cryocure-VT trial.

Older people who are initiating blood pressure (BP)-lowering medications appear to be at heightened risk of fractures, especially those who have dementia, as shown in a retrospective cohort study.

Use of landiolol, a highly selective and short-acting beta-1 blocker, demonstrates adequate safety and efficacy in terms of heart rate control among patients suffering from atrial tachyarrhythmias (ATs) and left ventricular (LV) dysfunction, suggest the results of a meta-analysis presented at EHRA 2024.

A novel “single-shot,” large-lattice pulsed field ablation (PFA) catheter that conforms to diverse left atrial and pulmonary vein anatomies is safe and efficacious for isolating pulmonary veins in patients with paroxysmal atrial fibrillation (AF), as shown in a first-in-human trial.

Giving oral anticoagulants to patients with device-detected atrial fibrillation (AF) and multiple comorbidities does not necessarily help lower the rate of cardiovascular events, according to a subgroup analysis of the NOAH-AFNET 6 trial.

The use of diltiazem, especially at doses exceeding 120 mg/d, appears to contribute to a heightened risk of serious bleeding compared with metoprolol in patients with atrial fibrillation (AF) who are receiving oral anticoagulant therapy, according to a retrospective cohort study.

In the placebo-controlled ORBITA-COSMIC* trial, an implantable coronary sinus reducer (CSR) does not increase transmural myocardial perfusion, but it reduces the frequency of angina and improves quality of life (QoL) in patients with no further antianginal options.